Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Contact: Study coordinator (Kangshun Zhu, Dr.) · zhksh010@126.com · +86-20-34156205
Contact: Principal Investigator (Kangshun Zhu, Dr.)
Mingyue Cai, Dr. (Sub-investigator)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

HCC - Hepatocellular Carcinoma · Conversion Therapy

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases · Hepatocellular Carcinoma · Immunotherapy

Abroad (travel likely)Recruiting

Guanzhou, China